2026-03-25 - CoA - Amgen v. Sanofi et al. - UPC_CoA_528/2024 UPC_CoA_529/2024
- Aktenzeichen:
- UPC_CoA_528/2024 UPC_CoA_529/2024
- Datum:
- Spruchkörper:
- Court of Appeal - Luxembourg (LU)
- Art:
- Decision
- Parteien:
- SANOFI-AVENTIS DEUTSCHLAND GMBH, SANOFI-AVENTIS GROUPE S.A., SANOFI WINTHROP INDUSTRIE S.A., and Regeneron Pharmaceuticals Inc. v. AMGEN, INC
Kernaussage: Withdrawal of rehearing application permitted, fee reimbursement denied.
2026-03-25 - CoA - Amgen
v.
Sanofi et al. - UPC_CoA_528/2024 UPC_CoA_529/2024
routine
Withdrawal of rehearing application permitted, fee reimbursement denied. Sanofi/Regeneron had filed an application for rehearing of the CoA's decision rejecting their revocation of EP 3 666 797. After Amgen consented, the CoA permitted withdrawal. The court confirmed that Rule 265.1 RoP applies not only to actions and appeals but also to applications for rehearing. Fee reimbursement was denied on a factual basis: the applicants had paid only one fee for two joined rehearing applications, so no reimbursement was due under Rule 370.9(b) RoP.